10/14/2024
Since 2018 with the first cases of being offered in Québec and all Eastern Canada at Sanomed clinic Brunswick Medical Center in Montreal, Dr Zorn and team have been fortunate to help forge the technology with research in technique standardization publications, research outcomes in men in retention and those with prostate volumes >80cc.
Rezūm office-based therapy, since its FDA approval in 2015 Boston Scientific Boston Scientific Urology with now 5 years data, has distinguished itself from other treatment options by its DURABLE improvement in objective clinical outcomes such as IPSS and BPH Impact Index, while being COST-EFFECTIVE and versatile in its ability to treat a variety of prostate gland morphologies. This includes men with a MIDDLE LOBE and those with frailty and anticoagulation. This treatment option demonstrates consistent LUTS relief, especially in small-to-moderate prostate sizes (30-80 cc). The use of convective heat transfer is unique and allows for localized treatment, avoiding damage to surrounding structures, thus providing an excellent safety profile and sexual function preservation.
With over 1000 MIST procedures performed todate, Dr Zorn and his team at BPHCanada have been designated as a center of excellent, not only for providing world-class care for their patients but equally important, delivering the personalized TLC care needed in their treatment journey. Furthermore, Dr Zorn and his team have helped train urologists across Canada, USA and internationally on REZUM therapy. Additionally, the supporting data has included REZUM in the national Canadian urology guidelines in 2018 and updated 2022 version.
To learn more about how REZUM can help you and the many treatment options now available for care, come visit us at www.bphcanada.com , call 514-443-0808 or email us at info@bphcanada.com.
Trust your prostate care in BPHCanada
